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PKD1 Induces p21waf1 and Regulation of the
Cell Cycle via Direct Activation of the JAK-STAT
Signaling Pathway in a Process Requiring PKD2
expression of other markers of proliferation (Klingel et
al., 1992).
In humans, at least two loci have been associated
with ADPKD. The major form, which accounts for 85%
of all cases, results from mutation of the PKD1 gene on
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domains including a cluster of 15 PKD repeats that may
mediate homophilic interactions (Ibraghimov-Beskrov-
naya et al., 2000). The short cytoplasmic carboxyl termi-Summary
nus contains a coiled-coil motif that is a site of binding
with the gene product of PKD2 (Qian et al., 1997). BasedAutosomal dominant polycystic kidney disease is
on its predicted structure, polycystin-1 is postulated tocharacterized by cyst formation in the kidney and other
be a plasma membrane nonkinase type receptor in-organs and results from mutations of PKD1 or PKD2.
volved in cell-cell/matrix interactions. Direct functionalPrevious studies suggest that their gene products
studies in support of this model are lacking, however.have an important role in growth regulation. We now
The second form of ADPKD, which is nearly indistin-show that expression of polycystin-1 activates the
guishable from the first, results from mutation of PKD2JAK-STAT pathway, thereby upregulating p21waf1 and
(Mochizuki et al., 1996). This gene encodes an integralinducing cell cycle arrest in G0/G1. This process re-
membrane protein of 968 amino acids that is likely aquires polycystin-2, a channel protein, as an essential
member of the TRP-like superfamily of channel proteinscofactor. Mutations that disrupt polycystin-1/2 binding
(Mochizuki et al., 1996; Tsiokas et al., 1999). Polycystin-2prevent activation of the pathway. Mouse embryos
is predicted to have six transmembrane spans with itslacking Pkd1 have defective STAT1 phosphorylation
amino and carboxyl termini both located within the cell.and p21waf1 induction. These results suggest that one
The carboxyl terminus of polycystin-2 mediates its inter-function of the polycystin-1/2 complex is to regulate
action with polycystin-1. We have recently shown thatthe JAK/STAT pathway and explain how mutations of
coexpression of polycystin-1 and -2 results in transloca-either gene can result in dysregulated growth.
tion of the latter to the plasma membrane where the
molecules coassemble to produce a new, nonselective,Introduction
calcium permeable cation current (Hanaoka et al., 2000).
Polycystin-2 is likely to be responsible for the channelAutosomal dominant polycystic kidney disease
properties of the complex (Gonzalez-Perrett et al., 2001).(ADPKD) is a common genetic disease (1/1000) and an
Molecular genetic studies of renal and hepatic cysticimportant cause of end stage kidney failure (ESKF; 5%;
tissue suggest that both PKD1 and PKD2 may be novelGabow, 1993). The disease is characterized by the grad-
members of the tumor suppressor class of genes. Clonal
ual replacement of normal renal parenchyma by cysts
somatic mutation of the wild-type allele is commonly
in a process that results in enlargement of the organ
found in epithelial cells isolated from individual cysts in
(from a length of 12 cm and weight of 0.5 kg to 18 both disorders (Qian et al., 1996; Watnick et al., 2000).
cm and weight of multiple kilograms) with significant The results of animal studies also support a “two-hit”
morbid consequences. Given the lack of an effective model of cyst formation. Mice heterozygous for targeted
therapy, much attention has been focused on defining mutations of either Pkd1 or Pkd2 have few cysts while
the pathogenesis of cyst formation. homozygous animals die in utero with severe cystic dis-
Several lines of evidence suggest that dysregulation ease (Lu et al., 1997, 2001; Wu et al., 1998).
of epithelial cell growth is a key step in this process. The observation that animals with homozygous muta-
The cysts are fluid-filled structures lined by epithelial tions of either Pkd1 or Pkd2 die in utero in the later
cells that are both hyperproliferative and hyperapoptotic stages of gestation suggests that both gene products
(Lanoix et al., 1996; Woo, 1995). Micropolyps are fre- are essential for normal development. The two models
quently observed projecting into the lumen, but onco- have similar patterns of renal development, with grossly
genic transformation is very uncommon (Torres, 1990), normal patterns of ureteric bud branching and mesen-
possibly due to the increased apoptosis that accompan- chymal induction. Abruptly, around E15, cystic struc-
ies the increased rate of growth. The cystic epithelium tures arise in the center of the organ, in the portion that
has a high mitotic rate in vivo as measured by PCNA is most developmentally advanced. It is postulated that
staining (Nadasdy et al., 1995) and increased levels of the polycystin complex is required for the final matura-
tion of renal epithelia.
Collectively, these studies suggest that the PKD1 and3 Correspondence: ggermino@jhmi.edu
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PKD2 gene products function in a cooperative manner ties are regulated by the relative ratio of cyclins and Cdk
inhibitors (CKIs) with which they are associated (Sherrto regulate growth and cellular differentiation. We have
recently described a cell culture system that provides and Roberts, 1999). The transition from G0/G1 into S
phase, a process that appears to be inhibited by poly-direct evidence in support of this hypothesis (Boletta et
al., 2000). Madin Darby canine kidney cell lines (MDCK) cystin-1, is specifically regulated by the activities of
Cdk2, Cdk4, and Cdk6. Therefore, we first examinedwith stable overexpression of the full-length cDNA for
human PKD1 had a reduced rate of growth, were more whether polycystin-1 exerted its effects by altering the
activity of any of these Cdks. As shown in Figure 2A,resistant to apoptosis, and spontaneously formed
branching tubules when cultured in three-dimensional the activity of Cdk2 was dramatically inhibited in both
the MDCKPKD1/Zeo clones and Hek293 cells with transientcollagen gels. In the current study, we describe a path-
way by which the polycystin complex mediates some of expression of polycystin-1, but not in MDCKZeo or in
Hek293 cells transfected with R4227X-F or empty vec-these effects and show that the function of this signaling
system is altered in Pkd1 null animals. tor. In contrast, polycystin-1 expression had no effect on
the level of activity of either Cdk4 or Cdk6. The reduced
activity of Cdk2 was not due to a decrease in the quantityResults
of either Cdk2 or its associated cyclin, cyclin E, since
the total protein level of each remained unchanged (Fig-PKD1 Expression Induces Accumulation of Cells
ures 2A and 2B). Instead, we found a significant increasein the G0/G1 Phase of the Cell Cycle
in the level of expression of p21waf1, one of the CKIsAs noted in the Introduction, we have recently devel-
known to inhibit Cdk2 activity, in each of the cell linesoped a series of MDCK cell lines with stable expression
overexpressing polycystin-1 and not in any of the nega-of either the full-length human cDNA for human PKD1
tive controls (Figure 2B). Consistent with this result, we(MDCKPKD1/Zeo) or a selectable marker (MDCKZeo; Boletta
found increased binding of p21waf1 to Cdk2 complex aset al., 2000). We found that the proliferation rate of the
assayed by immunoprecipitation studies (Figure 2A).MDCKPKD1/Zeo clones was approximately 50% that of con-
If polycystin-1 induces growth arrest in a p21waf1-trols (MDCKZeo) when grown on plastic dishes, an effect
dependent manner, one would expect that overexpres-even more pronounced when the clones were cultured
sion of PKD1-F in a cell line lacking p21waf1 should havesuspended in collagen matrix (data not shown). As the
little effect on its growth rate. We tested this predictionfirst step in defining the mechanism by which poly-
by comparing the BrdU incorporation rates of p21/cystin-1 exerts these effects, we tested whether inhibi-
and p21/ cells that had been cotransfected with GFPtion of proliferation was cell cycle dependent. Compar-
and either PKD1-F, R4227X-F, or empty vector. Trans-ing the cell cycle profile of two MDCKPKD1/Zeo clones (C8/
fected cells were sorted based on GFP expression and68 and G7/36) to that of a MDCKZeo clone (F6), we found
then analyzed for BrdU incorporation and polycystin-1that 75% and 89% of the C8/68 and G7/36 cells, but
expression. We found inhibition of BrdU incorporationonly 43% of the F6 cells were accumulated in G0/G1
only in p21/ cells that had been transfected with(Figure 1A).
PKD1-F (Figure 2C), even though PKD1-F and R4227X-FThese data suggested that overexpression of human
were expressed at equivalent levels (data not shown).polycystin-1 in a heterologous cell line could cause
These data suggest that p21waf1 is necessary in PKD1-growth arrest in G0/G1. Next, we examined the possibil-
mediated growth inhibition.ity that the effects were due to irrelevant clonal differ-
We next sought to determine whether the increasedences, a cell-type-specific effect of PKD1 expression,
level of p21waf1 that results from polycystin-1 expressionor a nonspecific toxic effect due to forced overexpres-
sion of a very large protein. We first created a construct is the result of upregulation of its transcription. To ad-
that expresses a clinically relevant mutant form of poly- dress this issue, we tested for increased activation of
cystin-1 of nearly identical length (R4227X-F) that has the p21waf1 promoter using a luciferase reporter assay.
a stop codon introduced in the middle of the coiled- The reporter construct WWP-Luc was cotransfected
coil motif (Hanaoka et al., 2000; Figure 1C). We then with PKD1-F, R4227X-F, or empty vector (pCI) into
cotransfected a plasmid encoding GFP with either an Hek293 cells and tested for luciferase activity at 24 hr.
epitope-tagged form of human wild-type PKD1 (PKD1-F) PKD1-F increased the luciferase activity about 8-fold,
or R4427X-F into two different human cell lines (Hek, whereas R4227X-F and pCI had negligible effects (Fig-
HeLa) and isolated transfected cells by fluorescence ure 2D).
activated cell sorting (FACS). Approximately 82% and The 2.4 kb promoter of the WWP-luc construct has
76% of the PKD1-F transfected Hek293 and HeLa cells, been previously reported to contain binding sites for
respectively, but only 55% and 56% of the mock-trans- p53 (2326 bp 5 of the TATA box) and STAT1 (640 bp
fected cells were accumulated in G0/G1 (Figure 1B). The 5 of the TATA box; El-Deiry et al., 1993; Chin et al.,
cell cycle profile of cells transfected with R4227X-F was 1996). We therefore tested whether polycystin-1 exerted
similar to that of cells transfected with empty vector its effects through either factor using modified p21 pro-
(Figure 1B). Immunoblot analysis revealed that approxi- moter constructs (Figure 2D). The first, DM-Luc, lacks
mately equal levels of expression were obtained for the p53 binding site and has been previously described
PKD1-F and R4227X-F, ruling out this variable as a trivial (El-Deiry et al., 1993), while for the other, we replaced
explanation for our findings. the STAT1 binding site of WWP-luc with an irrelevant
sequence of identical length to create a new construct,
WWP(M640)-Luc. Surprisingly, the level of luciferase ac-Polycystin-1 Inhibits Cdk2 Activity
by Upregulation of p21waf1 tivity induced by PKD1-F using DM-luc was similar to
that observed using WWP-luc. Consistent with this re-Progression through the cell cycle is controlled by a
family of cyclin-dependent kinases (Cks) whose activi- sult, PKD1-F failed to induce luciferase activity of pro-
Polycystin-1/2 Complex Activates JAK/STAT Pathway
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Figure 1. Effects of Polycystin-1 on Cell Cycle Progression
(A) Cell cycle profile of MDCKPKD1zeo clones C8/68 and G7/36 and a negative control, MDCKzeo F6. Cells were synchronized by withdrawal of
serum for 24 hr, reincubated with medium containing 10% serum for an additional 24 hr, and then stained with propidium iodide (PI) and
analyzed by FACS. The level of polycystin-1 expression in each sample as measured by immunoblot is shown on the right. The results of a
single study are shown, though similar results were obtained for each of three independent experiments.
(B) Cell cycle profile of Hek 293 (top left) and HeLa (bottom left) 24 hr after cotransfection with GFP and empty vector (pCI), PKD1-F, or
R4227X-F. Transfected cells were sorted based on GFP activity and then analyzed by FACScan. The panels on the right show the relative
levels of expression of PKD1-F and R4227X-F in Hek293 and HeLa cells, respectively.
(C) Schematic representation of the wild-type and mutant forms of polycystin-1 used for these experiments.
moters that contained either 13 or 15 tandemly arranged phorylated STAT1 exclusively in C8/68 (Figure 3B). Con-
sistent with these results, we detected STAT1 homodi-copies of the normal (PG13-Luc) or mutant (MG15) p53
binding site, respectively. In contrast, mutation of the mers by electrophoretic mobility-shift assay (EMSA) in
nuclear extracts of C8/68 but not in F6 (Figure 3C). Theseputative STAT1 binding site resulted in a complete loss
of luciferase activity. results suggest that STAT1 is constitutively activated in
C8/68 but not in control clone MDCKZeo.
Activation of STAT1 in Cells Overexpressing
Polycystin-1 PKD1 Inhibits Growth and Induces p21waf1 in STAT1
Null Cells after Reconstitution of STAT1 ActivitySTAT1 is a latent cytoplasmic transcription factor that
translocates to the nucleus after activation by phosphor- If STAT1 is responsible for inducing p21waf1 and cell
growth arrest in response to polycystin-1, then polycys-ylation (Schindler and Darnell, 1995). Given the results
of the p21-promoter assays, we tested for STAT1 activa- tin-1 should not have these effects when overexpressed
in cells lacking STAT1. To test this hypothesis, we coex-tion by PKD1 using two independent methods. First, we
measured the effect of polycystin-1 on the transcrip- pressed PKD1-F, R4227X-F, or empty vector (pCI) with
GFP in STAT/ (U3A) and parental STAT/ (2ftgh) cellstional activity of endogenous STAT1 in Hek293 using
a luciferase reporter assay. We cotransfected empty and selected for transfected cells by FACS. Immunoblot
analysis confirmed that equal levels of expression ofvector, PKD1-F, or R4227X-F with a reporter construct
(Sahni et al., 1999). Only PKD1-F induced a significant PKD1-F and R4227X-F were achieved (Figure 4A). As
predicted, PKD1-F specifically induced p21waf1 in 2ftghincrease (8-fold) of relative luciferase activity under
these conditions (Figure 3A). Similar results were ob- cells but not in U3A cells (Figure 4A). Coexpression of
STAT1 with PKD1-F in the U3A cells, however, resultedtained using Hela cells (data not shown). Next, we tested
whether endogenous STAT1 was fully activated in the in the usual upregulation of p21waf1 (Figure 4B). In parallel
experiments, neither R4227X-F nor pCI was capableMDCKZeo/PKD1 (C8/68) clone by testing for phosphoryla-
tion of S727 and Y701 using epitope-specific antibodies of inducing p21waf1 in these reconstitution experiments
(Figure 4B). Next, we compared the growth effects of(Figure 3B). While total STAT1 protein levels were no
different between the C8/68 and negative controls (F6), PKD1 expression in the U3A and 2ftgh cells. We coex-
pressed PKD1-F, R4227X-F, or pCI with GFP in cells ofwe found increased levels of tyrosyl- and serine-phos-
Cell
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Figure 2. PKD1 Expression Inhibits Cdk2 and Induces p21waf1
(A) Transfected Hek293 cells were identified by cell sorting as described in Figure 1B. The various Cdks were immunoprecipitated (IP) from
cells with either transient (Hek293; panel 1) or stable (MDCK; panel 2) expression of the constructs using specific antisera and then tested
for activity using an in vitro histone-1 (H1) phosphorylation assay (Medema et al., 1998). An aliquot of each IP product was analyzed by
immunoblot for both the quantity of its respective Cdk protein and the amount of associated p21waf1.
(B) Whole-cell lysates of the transfected Hek cells (panel 1) and stable MDCK clones (panel 2) shown in Figure 2A were analyzed by immunoblot
for expression levels of the indicated cyclins and CKIs. Transfected cells were identified by cell sorting as described in Figure 1B before cell
lysis.
(C) BrdU incorporation rates of parental p21/ (HCT116) and mutant p21/ (8054) cells transfected as indicated. The average of four
independent experiments, each performed in triplicate, is presented along with the standard errors of the mean.
(D) The p21waf1 promoter-reporter constructs are shown on top. Transcriptional activation of p21waf1 was measured using a p21waf1promoter-
luciferase reporter assay (bottom). PKD1-F, R4227X-F, or pCI was cotransfected with each of the p21waf1promoter-luciferase reporter constructs
using pCMV -gal as an internal standard for transfection efficiency. Luciferase activity was measured 24 hr after transfection and activity
was normalized to the level of -gal expression. The results of a single experiment performed in triplicate are presented, though similar results
were obtained for two additional experiments.
each line, sorted the cells based on GFP activity, and ase activity of the construct in two MDCKZeo clones (F6,
F8) and three MDCKPKD1/Zeo clones (G3, G7/36, C8/68;then determined their rates of growth using a BrdU in-
corporation assay. The results indicate that STAT1 is Figure 3E). Approximately 3-fold higher levels of lucifer-
ase activity were consistently observed in the PKD1essential for PKD1-mediated growth inhibition in this
cell culture system (Figure 4C). clones compared to the negative controls. We were,
however, unable to detect the tyrosyl-phosphorylated
form of activated STAT3 either in MDCKPKD1/Zeo or HepG2PKD1 Induces STAT3 Activation
Using an MDCK tubulogenesis cell culture system simi- cells transiently expressing PKD1-F. Likewise, we were
unable to detect either STAT3 homodimers or STAT1/3lar to ours, it was shown that HGF-mediated tubulogen-
esis was STAT3 dependent (Boccaccio et al., 1998). heterodimers in nuclear extracts of PKD1-expressing
cells by EMSA (Figure 3C). We attribute this negativeTherefore, we tested whether polycystin-1 expression
might also result in activation of STAT3 using a luciferase result to the relatively modest level of activation and
the typically transient nature of STAT3 phosphorylationreporter assay in HepG2 cells (whose endogenous
STAT3 levels are relatively high). We cotransfected (Bromberg et al., 1998).
empty vector, PKD1-F, or R4227X-F with the reporter
construct pSP72JunB-Luc (Matsumura et al., 1999) and Polycystin-1 Physically Interacts with JAK2
but Not JAK1 or Tyk2found that only PKD1-F induced a significant increase
(6-fold) of relative luciferase activity under these condi- We next sought to determine the mechanism by which
polycystin-1 induces the phosphorylation of STAT1. Intions (Figure 3D). Next, we compared the relative lucifer-
Polycystin-1/2 Complex Activates JAK/STAT Pathway
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Figure 3. Polycystin-1 Induces STAT1 Acti-
vation
(A) Transcriptional activity of STAT1 was
measured in Hek 293 cells using a luciferase
reporter assay. The results of a single experi-
ment performed in triplicate are presented in
Figures 3A, 3D, and 3E, though similar results
were obtained in two additional experiments
for each set of conditions.
(B) Activation of STAT1 was measured in
MDCKzeo clone F6 and MDCKPKD1zeo C8/68.
Cells were serum-starved for 24 hr prior to
harvesting. STAT1 was IP with -STAT1 and
immunoblotted with phosphoY701-specific
-STAT1 (pY-STAT1; top) and -STAT1 (mid-
dle). In the bottom, p-Y701-STAT1 was IP and
immunoblotted with antibodies specific for
phospho-S727.
(C) EMSA of total cell lysates (TL) and nuclear
extracts (NE) of HepG2 cells (lanes 1-6),
MDCKzeo clone F6 (lane 7), and MDCKPKD1zeo
C8/68 (lanes 8-10) serum-starved for 24 hr
and treated as indicated. The studies were
performed in a 4% nondenaturing gel using
32P-labeled hSIE probe. Arrows (A–C) identify
the STAT-3 homo-, STAT-1/3 hetero-, and
STAT-1 homodimers, respectively (Sadowski
et al., 1993). Supershift (SS) and competition
(comp.) assays were done using -STAT-1
and 100	 excess cold probe, respectively.
(D) STAT3 activation assay in HepG2 cells.
(E) STAT3 activation in MDCKzeo (F6, F8) and
MDCKPKD1zeo (C8/68, G3, G7/36).
some growth factor- and cytokine-dependent pro- phorylated before they can activate STATs. We therefore
tested whether any of the JAK2 bound to full-length orcesses, STATs are directly phosphorylated by the recep-
tor tyrosine kinase itself (ie. EGFR; Darnell, 1997). Poly- mutant polycystin-1 was phosphorylated. We coex-
pressed HA-JAK2 with PKD1-F or R4227X-F, immuno-cystin-1 lacks a kinase domain and is unable to activate
STAT1 directly by this mechanism. The majority of nonki- precipitated the complex, and probed for JAK2 activa-
tion using -phosphotyrosine antibodies. As shown innase cytokine receptors that signal through STATs in-
duce STAT phosphorylation through activation of a Figures 5A and 5C, phospho-JAK2 was found associ-
ated only with PKD1-F. These studies suggest that poly-member of the Janus kinase family of tyrosine kinases
(JAKs; Ihle, 1996). Of the four known members of the cystin-1 induces STAT1 activation by direct association
and activation of JAK2.JAK family (JAK1-3 and Tyk2), all but JAK3 are widely
expressed and thus could serve as potential partners
of polycystin-1. We therefore tested whether any of the Polycystin-1 Requires Polycystin-2
for Activation of JAK2ubiquitously expressed JAKs could physically associate
with polycystin-1 in cultured cells. For JAK1 and JAK2, The identical phenotypes that result from mutation of
PKD1 or PKD2 suggest that their gene products arewe cotransfected expression constructs of each with
PKD1-F, R4227X-F, or empty vector and tested for in likely to regulate a common signaling pathway (Qian et
al., 1997). As noted in the Introduction, the cytoplasmicvivo association using an immunoprecipitation assay.
Both PKD1-F and R4227X-F consistently coprecipitated carboxyl termini of their respective gene products asso-
ciate via interactions between their respective coiled-with HA-JAK2 regardless of whether we used -Flag-
coupled agarose beads (M2-beads) or -HA antibodies coil domains (Qian et al., 1997; Tsiokas et al., 1997).
Mutations, such as the one used in the current studyto perform the immunoprecipitation (Figure 5A). In con-
trast, neither protein was found complexed with JAK1 (R4227X) that altered the coiled-coil domain of either
protein, were found to greatly decrease interactions be-under identical conditions (Figure 5B). We next tested
whether polycystin-1 was able to associate with endog- tween the two proteins (Hanaoka et al., 2000). The obser-
vation that R4227X-F was able to bind but not activateenous JAKs. We transfected PKD1-F into Hek293 cells,
isolated polycystin-1 using M2-beads, and probed for JAK2 prompted us to consider whether the activation
of the JAK/STAT pathway by polycystin-1 required poly-JAK2 using -JAK antiserum (Figure 5C). In parallel,
we tested for JAK1 and Tyk2 binding using antiserum cystin-2.
One piece of evidence arguing against this hypothesisspecific for each. Although each of the JAKs was found
expressed at approximately equal levels in Hek293 cells was the observation that we had found JAK/STAT acti-
vation in the absence of exogenous PKD2 expression.(data not shown), only JAK2 coprecipitated with PKD1-F
(Figure 5C). These results suggested either that PKD2 was not re-
quired for this property of polycystin-1 or that endoge-As noted above, Janus kinases must become phos-
Cell
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Figure 4. STAT1 Is Necessary for PKD1-
Mediated Induction of p21waf1
(A) Immunoblot analyses of total cell lysates
of STAT1/ (U3A) and STAT1/ (2ftgh) cells
transfected as indicated were performed us-
ing -STAT1 (left), -Flag (right), and -p21waf1
antibodies (bottom). UT indicates untrans-
fected samples.
(B) Induction of p21waf1 by PKD1-F in U3A cells
by coexpression with STAT1. U3A cells were
cotransfected with pRcCMVSTAT1 and pCI,
PKD1-F, or R4227X-F and analyzed by immu-
noblot using -Flag (top), -STAT1 (middle),
and -p21waf1 antibodies (bottom).
(C) BrdU incorporation rates for STAT1/
(2ftgh) and STAT1/ (U3A) cells transfected
as indicated. The average of three indepen-
dent experiments, each performed in tripli-
cate, is presented along with the standard
errors of the mean.
nous levels of polycystin-2 were adequate in the cell Defective STAT1 Phosphorylation and p21waf1
Induction in Pkd1/ Mouse Embryoslines used for these studies. Using an-PKD2 antiserum,
we indeed found a modest level of polycystin-2 in each Given that all of our studies had been performed using
a cell culture overexpression system, we sought to de-of these cell lines. We subsequently identified a human
lymphoblastoid cell line, CB33 (Shim et al., 1998), that termine whether PKD1 also regulated this pathway in
vivo. We focused our search on the later stages of em-had no detectable expression of polycystin-2 and used
this to test the hypothesis (Figure 6A). PKD1-F, ex- bryonic development, since it has been previously
shown that p21waf is induced in differentiating tissues inpressed in the absence of PKD2, was able to bind to
HA-JAK2 but could not induce its phosphorylation nor a p53-independent manner (Parker et al., 1995). The
E14.5–E15.5 interval was targeted for analysis, since thisinduce upregulation of p21waf (Figure 6B). Coexpression
of PKD1-F with PKD2, however, resulted in both HA- is the stage when renal cysts are first observed and the
last for which viable homozygous null animals can beJAK2 phosphorylation and induction of p21waf1. Control
studies performed using R4227X, Myc-R742X (a mutant reliably obtained. In pilot studies of wild-type (Pkd1/)
and Pkd1/ heterozygotes (n 
 5 for E14.5, n 
 3 forform of polycystin-2 incapable of interacting with poly-
cystin-1; Hanaoka et al., 2000), and empty vector E15.5) and Pkd1/ null embryos (n 
 2 for each stage)
at E14.5 and E15.5, we found that the level of p21waf1showed that these were specific effects of polycystin-1.
Finally, we tested whether polycystin-2 was itself ca- was relatively low at E14.5 in both sets of animals and
then markedly higher at E15.5 in the normals (data notpable of binding JAK2 and thereby able to promote
JAK2 transphosphorylation when polycystin-1 and -2 shown). In contrast, the level of p21waf1 remained low in
the homozygous animals at E15.5. We then focused ourcoassembled at the plasma membrane. We coex-
pressed HA-JAK2 with PKD2 in CB33 cells and tested studies on E15.5 and expanded the size of each set to
include a total of 7 Pkd1/and 18 Pkd1/ and Pkd1/for interaction using an immunoprecipitation assay. The
proteins failed to coprecipitate in the absence of poly- animals from 5 litters. All studies were performed and
interpreted in a blinded fashion, and representative re-cystin-1 (data not shown). Taken together, these results
suggest that polycystin-2 is not necessary for the bind- sults are presented in Figure 7A. Identical results were
obtained: all null animals had much lower levels of p21wafing of JAK2 to polycystin-1, but is essential for its activa-
tion and the subsequent induction of p21waf1. than normal littermates. All blots were reprobed after
Polycystin-1/2 Complex Activates JAK/STAT Pathway
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Figure 5. JAK2 Associates with Both Mutant
and Wild-Type Polycystin-1, but Is Phosphor-
ylated Only by the Latter
(A) Total cell lysates of Hek 293 cells cotrans-
fected with pRK5-HA-JAK2 and either pCI,
PKD1-F, or R4227X-F were subject to IP us-
ing M2 beads or -HA. IP products were re-
solved in SDS-PAGE and immunoblotted (IB)
with -PKD1CT to detect polycystin-1 (top),
-HA to detect JAK2 (middle), and -pY to
detect phospho-JAK2 (JAK2P) (bottom).
(B) Same experimental design as in Figure
5A, except JAK1 was used for transfection
rather than HA-JAK2 and -JAK1 was substi-
tuted for -HA.
(C) Total cell lysates of Hek 293 cells trans-
fected with pCI, PKD1-F, or R4227X-F were
subject to IP using M2 beads (-Flag) or
-JAK2. IP products were analyzed by immu-
noblot (IB) using -PKD1CT (top), -JAK2
(middle), and -phosphotyrosine (-pY,
bottom).
stripping with antibodies for -actin to verify equal load- was absent and p21waf1 staining was significantly re-
duced in these same tissues in Pkd1 null embryos.ing in each lane (Figure 7B).
We reasoned that if the normal upregulation of p21waf1
that was observed at E15.5 was regulated at least in Discussion
part by polycystin-1, then it should occur via activation
of STAT1. Using the same set of samples tested for Studies of murine and human cystic tissues and cells
suggest that altered regulation of renal tubular epithelialp21waf1 expression, we assayed for pY701-STAT1 with
epitope-specific antiserum. As before, all studies were cell growth and a block in terminal differentiation are
key factors in the pathogenesis of ADPKD. Our in vitroperformed in a blinded fashion. Representative results
are presented in Figure 7C. pY701-STAT1 was present model of PKD1-induced tubulogenesis recently pro-
vided evidence that polycystin-1 might have a directin all of the Pkd1/ and Pkd1/samples (n 
 14) and
greatly reduced in each of the 5 Pkd1/ animals. We role in the regulation of these properties (Boletta et al.,
2000). The present study describes a complete signalingexcluded differences in total STAT1 expression by stan-
dard immunoblot studies as a trivial explanation for pathway by which polycystin-1 directly mediates some
of these effects. We have shown that overexpression ofthese findings (Figure 7D). It is also important to note
that all E15.5 nulls used in this study were viable, as PKD1 transmits its growth inhibitory signals from the
cell surface to the nucleus via direct activation of theindicated by both standard clinical assessments and a
battery of 10 biochemical markers that cover a range JAK-STAT pathway. Our data suggest that increased
expression of p21waf1 is primarily responsible for mediat-of cellular stress response pathways and signaling sys-
tems (See Supplemental Data at http://www.cell.com/ ing the growth-suppressing effects of PKD1 in our ex-
perimental systems. These results are consistent withcgi/content/full/109/2/157/DC1). The observation that a
total of 12 proteins had essentially identical levels of previous reports that have shown that sustained activa-
tion of STAT1 can lead to growth inhibition (Brombergexpression in the nulls versus normals/heterozygotes
strongly argues against our findings being nonspecific et al., 1998). We also found that PKD1 is likely to signal
through this pathway in vivo during fetal development.phenomena.
In a final set of experiments, we sought to relate the Murine embryos that lack Pkd1 have greatly reduced
levels of STAT1 activation and p21waf1 induction. Theseactivation of STAT1 directly to polycystin-1 function. We
reasoned that if the latter molecule is in fact responsible data suggest that PKD1 may be an important regulator
of the normal developmental pattern of p21waf1 ex-for the upregulation of p21waf1, one would expect overlap
in their expression patterns with colocalization in the pression.
We also present evidence suggesting that the poly-same cell types in this key developmental phase. This
indeed was what was observed by immunohistochemi- cystin-JAK2 pathway can activate STAT3. Although the
function of STAT3 as regulated by PKD1 has not yetcal studies. Polycystin-1 was widely expressed at a low
level in multiple tissues that also were sites of p21waf1 been established, we postulate that it may help to medi-
ate the tubulogenic properties of polycystin-1 in our inexpression (Figures 7E–7G). As expected, polycystin-1
Cell
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also observed induction of p21waf1 expression by HGF,
though the authors did not comment on the activation
status of STAT1. We speculate that STAT1 is also acti-
vated in MDCK cells by HGF and that both STATs may
be required for HGF and PKD1-induced tubulogenesis
in this cell line.
The JAK-STAT pathway is known to mediate the sig-
naling of numerous cytokines and growth factors (Dar-
nell, 1997; Leaman et al., 1996) and has been implicated
in the regulation of a wide range of cellular processes
such as proliferation, differentiation, and survival and
host resistance to pathogens (Leonard and O’Shea,
1998). Although much of the work has focused on defin-
ing the role of JAK-STAT in modulating the immune
response, some JAKs and STATs are essential in both
mammalian and invertebrate embryonic development
(Duncan et al., 1997; Hou and Perrimon, 1997). Specific-
ity of function is defined in part by the particular combi-
nation of receptors, JAKs, and STATs that are activated
in response to a stimulus.
In the case of STAT1, a wide variety of growth factors
and cytokines have been shown in cell culture systems
to induce its activation. Initial studies of STAT1 null mice,
however, have suggested that STAT1 utilization is re-
markably specific to the interferon system in vivo (Durbin
et al., 1996; Meraz et al., 1996). STAT1 null animals are
viable, have apparently normal kidneys, and have no
obvious defects in any other cytokine or growth factor
signaling pathway. Moreover, mice homozgyous for null
alleles of p21waf1 also have a normal developmental pro-
file (Deng et al., 1995). One obvious challenge is reconcil-
ing our data with these results.
We suggest a number of reasons why the STAT1 and
p21waf1 null phenotypes differ from that of Pkd1 null ani-
mals. First, recent studies suggest that there are likely
to be other functions for STAT1 beyond those initially
attributed to it by the original pair of “knockout” studies.
For example, chondrocyte development and bone mor-
phogenesis have recently been found to be aberrant in
STAT1 null animals (Sahni et al., 1999). Interestingly,
these are prominent sites of both p21waf1 and poly-
cystin-1 expression, and recent studies suggest a criti-
cal role for Pkd1 in normal bone development (Lu et al.,
2001). A second reason that the Pkd1/ and STAT1/
phenotypes may differ is that polycystin-1 activates
both JAK2 and probably STAT3. The latter molecules
have been shown by gene-targeting studies to have
essential roles in normal embryonic development
(Takeda et al., 1997). Animals that are homozygous nullFigure 6. Expression of PKD2 Is Essential for PKD1-Induced JAK2
for either gene die by day 12.5, (Takeda et al., 1997;Phosphorylation
Neubauer et al., 1998; Parganas et al., 1998) prior to the(A) Endogenous levels of polycystin-2 in different cell lines. Polycys-
development of the metanephric kidney and the firsttin-2 was IP with -PKD2CT, resolved in 6% SDS-PAGE, and immu-
noblotted (IB) with the same antibody. renal cysts in mutant Pkd1 animals (Lu et al., 1997).
(B) CB33 cells were cotransfected with pRK5-HA-JAK2 and a combi- Furthermore, mounting evidence suggests that JAK2 is
nation of other expression constructs as indicated on top and har- likely to be a central regulator of many cytokine-induced
vested 12 hr later. An equal aliquot of each cell lysate was then signaling events in addition to its role in STAT-mediated
subject to IP using M2 beads (-Flag), -HA, and -Myc. The respec-
transcriptional activation (Yeh and Pellegrini, 1999). Fi-tive IP products were resolved by PAGE and then analyzed by IB
nally, we hypothesize that PKD1 functions as a masterusing antisera as indicated. The bottom panel shows the level of
regulator of multiple processes. Hits to only one or twop21waf1 expression in the total cell lysate of each culture.
target pathways are insufficient to produce a cystic phe-
notype, just as isolated loss of any other tumor suppres-
vitro model since it has previously been shown to regu- sor by itself usually does not result in cancer. Embryonic
late this process in an HGF model of tubulogenesis (Boc- death (when there is homozygous loss of Pkd1) and
cystic disease (when there is a combination of germlinecaccio et al., 1998). Interestingly, the earlier study had
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Figure 7. p21waf1 Expression in Pkd1/ Em-
bryos
(A) Immunoblot of total protein lysates pre-
pared from E15.5 embryos (300 g/lane) us-
ing -p21waf1. The genotype of each specimen
is indicated at the top of each lane.
(B) Same blot in (A), stripped, and then re-
probed with an antibody specific for -actin
to control for protein loading.
(C) PhosphoY701-STAT1 (pY-STAT) was im-
munoprecipitated from total lysates of the
samples used in (A) and then immunoblotted
using a different epitope-specific pY701-
STAT1 antibody. The arrow indicates the po-
sition of pY-STAT1.
(D) Immunoblot showing total STAT1 levels
in samples used in (A)–(C).
(E) Immunohistochemical localization of poly-
cystin-1 and p21waf1 in Pkd1/ embryos at
day E15.5 viewed at 50	 magnification. Red
boxes highlight sections imaged at higher
magnification in (F) and (G).
(F) Cartilage of Pkd1/ and Pkd1/ animals
stained with -PKD1CT and -p21waf1 anti-
sera, viewed at 100	.
(G) Kidneys of Pkd1/ and Pkd1/ animals
stained and imaged as in (F).
and acquired inactivation) are the net effects that result pathway by polycystin-1 occurred in the apparent ab-
sence of any exogenous factors (See Supplemental Datafrom dysregulation of multiple pathways. We believe our
data strongly suggest that the JAK/STAT pathway is at http://www.cell.com/cgi/content/full/109/2/157/DC1).
One possibility is that the PKD1 cells are functioningone of them.
While the PKD1-mediated activation of JAK-STAT sig- in an autocrine manner, releasing a soluble factor in
too low a concentration to be effective in conditionednaling follows the general schema described for this
system, there are two unique aspects worth emphasiz- medium. An alternative explanation is that the relatively
high level of expression of polycystin-1 that was achieveding. Most previously described examples of STAT acti-
vation by Janus kinases have required exogenous cyto- (compared to endogenous levels) was itself sufficient
to induce receptor dimerization and activation, as haskines or growth factors for induction (Darnell, 1997). One
notable feature of our study is that activation of this been reported for receptor tyrosine and Janus kinases
Cell
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(Rui et al., 1997). A final possibility is that the mechanism JAK-STAT signaling systems might also require a ubiq-
of activation of JAK2 by polycystin-1 differs from the uitously expressed cofactor for their proper function.
conventional one. Finally, the data presented in this study provide a
The second novel aspect of the PKD1-regulated sys- mechanistic explanation for how mutations of either
tem is that it requires polycystin-2, a probable channel PKD1 or PKD2 result in a similar phenotype of hyper-
protein, as an essential cofactor. Polycystin-1 is consti- proliferative cystic epithelia. Our results suggest that
tutively bound to JAK2, but the latter becomes activated neither polycystin is by itself capable of activating the
only when the molecules are coexpressed with polycys- JAK-STAT pathway. The role of polycystin-2 in polycys-
tin-2. The fact that polycystin-2 cannot bind to JAK2 in tin-1-mediated JAK2 activation further proves that both
the absence of polycystin-1 excludes the possibility that proteins are the partners of a common signaling path-
it is responsible for bringing a second JAK to the com- way whose disruption results in the indistinguishable
plex. To date, two positive regulators of Janus kinases PKD1 and PKD2 phenotypes.
have been identified. STAM-1 has been reported to as-
Experimental Proceduressociate with JAK2 and JAK3 via an SH3 domain and
has been shown to enhance cytokine-dependent signal
Plasmid Constructs and Transfectionstransduction (Takeshita et al., 1997). The adaptor pro-
Flag-tagged full-length PKD1 (PKD1-F), R4227X-F, M-PKD2, andtein, SH2-B, also has been shown to be a potent activa-
M-R742X have been previously described (Hanaoka et al., 2000).
tor of JAK2 through binding of its SH2 domain to tyrosyl- WWP-Luc, PG13-Luc, and MG15-Luc were obtained from B. Vo-
phosphorylated JAK2 (Rui and Carter-Su, 1999). In both gelstein. WWP (M640)-Luc was constructed by replacing the STAT
cases, it seems likely that JAK2 activation precedes binding sequence (5-CTTCCCGGAA-3) of WWP-Luc at position
640 nt 649 nt with scrambled sequence (5-GGGGTACCCC-3).binding of the adaptor molecule and subsequent amplifi-
pRcCMV STAT1 was a gift from J. Darnell. pTK-IRF1-Luc and TK-luccation or stabilization of signal. Polycystin-2 has neither
and pSP72JunB-Luc were obtained from D. Levy and I. Matsumura,an SH2 nor an SH3 domain and is unlikely to function
respectively. pRK5-JAK1 and pRK5-JAK2-HA were provided by J.
as a kinase. These observations suggest that the poly- Ihle. Cells were transfected using Lipofectamine 2000 (Gibco/BRL),
cystin-1/2 complex may activate JAK-STAT via a novel according to the manufacturer’s instructions. Cells were harvested
mechanism. 24 hr after transfection except where otherwise stated.
We propose three possible explanations for our find-
Cell Sorting, BrdU Labeling, and Cell Cycle Analysisings. First, polycystin-2 may serve to facilitate homo-
Twenty-four hr posttransfection, cells were detached by trypsiniza-typic interactions between two polycystin-1 molecules.
tion, resuspended in phosphate buffer saline (PBS), and sortedPolycystin-1 and -2 are known to associate via coiled-
based on GFP expression by FACS. For BrdU labeling, an identicalcoil domains in their C termini, and the presence of
procedure was used for both the stable MDCK cell lines and cells
polycystin-2 may stabilize or enable binding of a second with transient expression of the various constructs. Cells were pulse
polycystin-1 molecule. The close proximity of two poly- labeled with 20 M BrdU (Boehringer Mannheim) for 4 hr, washed
cystin-1 molecules could then allow JAK2 transphos- with PBS, harvested by trypsinization, and fixed in 70% ethanol at
20C overnight. Cells were then rinsed with PBS, denatured withphorylation. This assumption is consistent with the pre-
2N HCl/0.5% Triton X-100 for 30 min at room temperature, neutral-vious observation that homodimeric interaction of a
ized with 0.1 M sodium borate buffer, (pH 8.5), blocked with 2%variety of receptors (growth hormone, prolactin, throm-
BSA/0.1% Tween 20 in PBS for 1 hr at room temperature, and
bopoietin, and erythropoietin) also results in JAK2 acti- incubated with fluorescein-conjugated -BrdU antibody (Phar-
vation (Yeh and Pellegrini, 1999). A second possibility Mingen; 1:100 dilution) for 30 min. After three washes, nuclei were
is that the interaction between polycystin-1 and -2 might treated with 100 U/ml RNase and 20 M of propidium iodide (PI)
for 30 min. At least 10,000 cells were scored using a FACScanresult in a conformational change that stabilizes JAK2
flow cytometer. Cell cycle distribution was analyzed with Cellquestin an active state, possibly by protecting phosphorylated
software.tyrosine residues from tyrosine phosphatases. Likewise,
the interaction of polycystin-1 and -2 might disrupt or
Immunoprecipitation and Western Blot Analysisinhibit binding of other JAK2 inhibitors such as JAB/
Cells were lysed in 10 mM sodium phosphate buffer (pH 7.2) con-
SOCS-1, SHP-1, or other tyrosine phosphatases (Sasaki taining 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1% Triton X-100,
et al., 1999; Yasukawa et al., 1999; Krebs and Hilton, and complete protease inhibitors cocktail (Roche, CA). A mix of
2000; Irie-Sasaki et al., 2001). The final consideration is phosphatase inhibitors was also added to the lysis buffer for studies
of phosphorylation status of JAKS/STATs. Recombinant protein wasthat the novel channel properties that result from coas-
immunoprecipitated using M2-agarose beads (Sigma) or a mousesembly of polycystin-1 and polycystin-2 at the plasma
monoclonal Myc-antibody (Roche) and Sepharose G agarose beads.membrane are somehow responsible for activation of
Western blot analyses were performed using either -Flag (SantaJAK2. Given that the channel has the highest permeabil-
Cruz) or -PKD1CT (Boletta et al., 2000) for polycystin-1 and either
ity for calcium, one intriguing possibility is that calcium
-Myc (Roche) or -PKD2CT (Boletta et al., 2000) for polycystin-2.
influx mediated by the channel could activate a signaling The following antibodies were obtained from Santa Cruz Biotechnol-
cascade, which in turn is responsible for the phosphory- ogy (-HA, -p21waf1, -p16, -p19, -Cdk4, -Cdk6, -cyclin D,
-cyclin E, JAK1, JAK2, Tyk2, and -phosphotyrosine) andlation and activation of JAK2.
Transduction Laboratory (-Cdk2, -STAT1, and -pY-STAT1). D.There is one interesting implication of this work that
Frank provided -pS-STAT1 (Frank et al., 1997).warrants further study. In the case of PKD1, it was the
known relationship between polycystin-1 and -2 that
Luciferase and EMSA Assaysprompted us to hypothesize that the latter molecule was
Cells transfected with luciferase reporter plasmids, pCMV-gal, and
a key partner in the pathway and then to search for a various experimental constructs were plated in triplicate in six-well
cell line that lacked polycystin-2. This approach allowed plates. Cells were washed twice with 3 ml of PBS and then lysed
us to show that polycystin-2 is essential for normal poly- in 0.4 ml (per well) of 1	 lysis buffer (Promega) for 10 min at room
temperature. After a brief spin to pellet large debris, 20l of superna-cystin-1 function. We question whether any of the other
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tant was added to 100 l of reconstituted luciferase assay reagent Durbin, J.E., Hackenmiller, R., Simon, M.C., and Levy, D.E. (1996).
Targeted disruption of the mouse Stat1 gene results in compromised(Promega). Light emission was detected using a luminometer. EMSA
was performed using both whole-cell lysates and nuclear extracts innate immunity to viral disease. Cell 84, 443–450.
as described by Sadowski et al. (1993). HepG2 cells were treated El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R.,
with either 1000 /ml interferon- or 4 ng/ml of interleukin-6 for 15 Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B.
min before harvesting. The hSIE6 sequence (m67; Sadowski et al., (1993). WAF1, a potential mediator of p53 tumor suppression. Cell
1993) was used as a probe. 75, 817–825.
Consortium, E.P.K.D. (1994). The polycystic kidney disease gene
In Vivo Studies encodes a 14 kb transcript and lies within a duplicated region on
We generated through gene targeting a line of mice in which exons chromosome 16. Cell 77, 881–894.
2–3 of murine Pkd1 were replaced with the lacZ gene cloned in-
Frank, D.A., Mahajan, S., and Ritz, J. (1997). B-lymphocytes fromframe to the 5 end of exon 2 of Pkd1 (K.P., unpublished data). All
patients with chronic lymphocytic leukemia contain signal trans-Pkd1/ animals died in utero, and renal and pancreatic cysts were
ducer and activator of transciption (STAT)1 and STAT3 constitutivelyevident in the E15.5 Pkd1/ embryos as has been previously de-
phosphorylated in serine residues. J. Clin. Invest. 100, 3140–3148.scribed (Lu et al., 2001). Timed pregnancies of Pkd1/ crosses were
Gabow, P.A. (1993). Autosomal dominant polycystic kidney disease.harvested at E14.5 or 15.5 and all viable fetuses were either snap
N. Engl. J. Med. 329, 332–342.frozen in liquid nitrogen or fixed for 24 hr in 10% buffered formalin
after removal of yolk sacs that were used for genotyping. The frozen Gonzalez-Perrett, S., Kim, K., Ibarra, C., Damiano, A.E., Zotta, E.,
whole embryo was pulverized in liquid nitrogen and immediately Batelli, M., Harris, P.C., Reisin, I.L., Arnaout, M.A., and Cantiello,
lysed in 50 mM Hepes lysis buffer, (pH 7.5), containing 150 mM H.F. (2001). Polycystin-2, the protein mutated in autosomal dominant
NaCl, 1.5 mM MgCl 2, 1 mM EDTA, 10% glycerol, 1% Triton X-100, polycystic kidney disease (ADPKD), is a Ca2-permeable nonselec-
and a mix of phosphatase and protease inhibitors. Whole-cell lysate tive cation channel. Proc. Natl. Acad. Sci. USA 98, 1182–1187.
was used for p21waf1 and -actin measurement and pY-STAT1 was Hanaoka, K., Qian, F., Boletta, A., Bhunia, A.K., Piontek, K., Tsiokas,
measured following immunoprecipitation using Y701-phospho- L., Sukhatme, V.P., Guggino, W.B., and Germino, G.G. (2000). Co-
specific STAT1 antibody. Immunohistochemistry was performed us- assembly of polycystin-1 and -2 produces unique cation-permeable
ing the Innogex IHC kit according to the manufacturer’s recommen- currents. Nature 408, 990–994.
dations. Samples were boiled for 1.5 min and then simmered for 10
Hou, X.S., and Perrimon, N. (1997). The JAK-STAT pathway in Dro-min in the kit’s target retrieval buffer prior to incubation with the
sophila. Trends Genet. 13, 105–110.-PKD1CT1 and -p21waf1 antisera, respectively. -PKD1CT was
Hughes, J., Ward, C.J., Peral, B., Aspinwall, R., Clark, K., San Millan,used at a dilution of 1:15 while -p21waf1 was used at 1:150.
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